

HEO Popup

Thiopurine Therapy Poor Metabolizer Rules

Genomic testing has been performed and indicates that this patient is at VERY HIGH risk for myelotoxicity with thiopurine therapy.

This patient has been tested for TPMT variants which has identified the presence of two copies of a risk allele which is associated with poor metabolism of thiopurine therapy. Poor metabolizers have highly reduced or absent TPMT activity and are at very high risk for myelotoxicity when treated with thiopurine therapy.
(See StarPanel for patient-specific TPMT gene result.)

Standard dosing of thiopurine therapy is contraindicated. If using thiopurine therapy, please select a reason:

- Leukemia treatment
- No alternate treatment, pursuing significant dose reduction
- Other (Specify)

Click here for [more information](#)

NOTE: The Vanderbilt P&T Committee has approved this recommendation based on the detailed review of the literature and consensus guidelines.

HEO Popup

Thiopurine Therapy Intermediate Metabolizer Rules

Genomic testing has been performed and indicates that this patient is at INCREASED risk for myelotoxicity with thiopurine therapy.

This patient has been tested for TPMT variants which has identified the presence of one copy of a risk allele which is associated with intermediate metabolism of thiopurine therapy. Intermediate metabolizers have reduced TPMT activity and are at increased risk for myelotoxicity when treated with thiopurine therapy.
(See StarPanel for patient-specific TPMT gene result.)

Dose reduction and close monitoring is strongly recommended if thiopurine therapy is continued.

Click here for [more information](#)

NOTE: The Vanderbilt P&T Committee has approved this recommendation based on the detailed review of the literature and consensus guidelines.